When it comes to low float penny stocks that have been sliding down the charts like a wheel of cheese on a Wisconsin hillside, no biotech out there can really compare with how poor Access Pharmaceuticals Inc. (ACCP) had been performing. Bouncing off a near-new 52 week from Friday, shares of ACCP stock suddenly revived themselves today as they surpassed their highest volume trading on record for the last 3 years without having to issue any new updates. As the Company continues to line up their MuGard™ patent protection around the globe, gains are being booked in advance of an upcoming reverse stock split which was approved on May 15, 2014.
Our Next Pick Is Coming Soon!
Click HERE To Make Sure You Don’t Miss Any Of Our Hot Penny Stock Alerts!
ACCP Stock Quote
Market Cap: 6.79M
Last: 0.26 ▲ +0.0251 (+10.69%)
Dollar Volume: $273,502
14-Day RSI: 40.67%
1st Resistance Point: 0.3293
1st Support Level: 0.2114
52Wk High: 0.60
52Wk Low: 0.213
Access Pharmaceuticals is preparing themselves for looks to be a major move in their product placement within the licensed territories, U.S., Chaina and Korea, for their MuGard®, the one marketed product of the biotech firm which manages oral mucositis, a frequent side-effect of cancer therapy for which there is no established treatment. Although the niche market may seem as if it is minuscule due to the unfamiliarity of mucositis, the market is said to be worth in excess of $1.0 billion world-wide.
Access Pharmaceuticals’ MuGard® was launched in the U.S. in 2010 after receiving a marketing allowance from the FDA which has since been licensed exclusively to AMAG Pharmaceuticals, Inc. for commercialization. Access Pharmaceuticals booked an upfront licensing fee of $3.3 million last year when the deal was signed and still gets quarterly tiered, double-digit royalties on net sales from AMAG which was worth $62,000 for first quarter of 2014.
The numbers may seem small in comparison to the $1.162 million of MuGard sales that were recorded during the first quarter of 2013 in the U.S. alone, however, with Access Pharmaceuticals having licensed MuGard to RHEI Pharmaceuticals for commercialization in China and Hanmi Pharmaceutical Co. Ltd. for the commercialization in South Korea, Access Pharmaceuticals now has the ability to focus on their current product candidates:
• ProctiGard™ is our product being developed for the management of radiation proctitis, a frequent side effect of radiation treatment to the pelvic region. Radiation proctitis, or RP, is the inflammation and damage to the lower portion of the colon after exposure to x-rays or ionizing radiation as part of radiation therapy. RP is most common after treatments for cancer, such as cervical, colon and prostate cancer. RP can be acute, occurring within weeks of initiation of therapy, or can occur months or years after treatment. Access intends to develop ProctiGard in a manner similar to the development of MuGard, which may include confirmatory clinical trials, with the objective of commercialization in collaboration with marketing partners globally.
• LexaGard™, is our proprietary formulation of the generic pharmaceutical agent, amlexanox, a drug with known anti-inflammatory and anti-allergic properties that has been approved and used in the US, Japan and other countries. Access is positioning LexaGard for treatment of conditions of the upper gastrointestinal tract including Barrett’s esophagus and esophagitis.
• CobOral™ is our proprietary preclinical nanopolymer oral drug delivery technology based on the natural vitamin B12 oral uptake mechanism. We have developed product candidates based upon the CobOral delivery technology, and have conducted sponsored product development for oral delivery of a number of peptides and RNAi therapeutics. The CobOral platform technology is available for partnering.
• CobaCyte™ — mediated targeted delivery is a preclinical technology that makes use of the fact that cell surface receptors for vitamins such as B12 are often overexpressed by certain cells including many cancers. This technology uses nanopolymer constructs to deliver more anti-cancer drug to tumors while protecting normal tissues. The CobaCyte platform technology is available for partnering.
With Hong Kong now booked as another territory where MuGuard has patent protection, the upcoming reverse split is likely in advance of some major moves forwards with one or more of the Company’s current product candidates. Seeing as how ACCP loves to take its time to bounce off of it’s neat lows before hitting it’s head on 0.60, today’s spark of interest on the heels of the Aegis Capital Corp. funding project underway should be more than enough to get longs interested in ACCP in advance of heading to the NASDAQ.
Looking for the Best Penny Stocks to Buy?
Click HERE To Receive FREE Penny Stock Alerts
About ACCP Stock
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company focused on developing a range of pharmaceutical products primarily based upon our nanopolymer chemistry technologies and other drug delivery technologies.
Issued and Outstanding: 26,104,443
Last 5 Trading Sessions:
As it is now, ACCP would be a fantastic penny stock to be looking to go long on. With hints of an uplisting to the NASDAQ within the recent S-1 filing and a reverse split on the horizon, ACCP stock could become a huge winner for those with the patience to wait out the long period it usually takes for the PPS to hit its ceiling again.